Anti-AQP4 disease
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Anti-AQP4 disease | |
|---|---|
 | |
| Synonyms | Neuromyelitis optica spectrum disorder (NMOSD) |
| Pronounce | N/A |
| Specialty | Neurology |
| Symptoms | Optic neuritis, transverse myelitis, area postrema syndrome |
| Complications | N/A |
| Onset | Typically in adulthood |
| Duration | Chronic |
| Types | N/A |
| Causes | Autoimmune attack on aquaporin-4 |
| Risks | Female gender, Asian or African descent |
| Diagnosis | Serology for anti-AQP4 antibodies, MRI |
| Differential diagnosis | Multiple sclerosis, acute disseminated encephalomyelitis |
| Prevention | N/A |
| Treatment | Immunosuppressive therapy, plasmapheresis, intravenous immunoglobulin |
| Medication | Methylprednisolone, rituximab, azathioprine |
| Prognosis | Variable, can lead to significant disability |
| Frequency | Rare |
| Deaths | N/A |
Anti-AQP4 disease is an autoimmune disorder that primarily affects the central nervous system (CNS). It is characterized by the presence of autoantibodies against aquaporin-4 (AQP4), a water channel protein found in the astrocytes of the CNS. This condition is closely related to neuromyelitis optica spectrum disorder (NMOSD).
Pathophysiology[edit]
Anti-AQP4 disease is caused by the production of autoantibodies that target the AQP4 protein. AQP4 is predominantly expressed in the astrocytic endfeet at the blood-brain barrier and in the optic nerves. The binding of these antibodies to AQP4 leads to complement activation and inflammatory damage to the central nervous system, resulting in demyelination and neuronal damage.
Clinical Features[edit]
The clinical presentation of anti-AQP4 disease can vary, but common symptoms include:
- Optic neuritis: Inflammation of the optic nerve, leading to vision loss and eye pain.
- Transverse myelitis: Inflammation of the spinal cord, causing weakness, sensory loss, and bladder dysfunction.
- Area postrema syndrome: Characterized by nausea, vomiting, and hiccups due to involvement of the area postrema in the brainstem.
Diagnosis[edit]
The diagnosis of anti-AQP4 disease is based on clinical presentation, magnetic resonance imaging (MRI) findings, and the detection of anti-AQP4 antibodies in the serum or cerebrospinal fluid (CSF). MRI typically shows lesions in the optic nerves, spinal cord, and brainstem.
Treatment[edit]
Treatment of anti-AQP4 disease involves the use of immunosuppressive therapy to reduce inflammation and prevent relapses. Common treatments include:
- Corticosteroids: Such as methylprednisolone, used for acute attacks.
- Immunosuppressants: Such as azathioprine, mycophenolate mofetil, and rituximab.
- Plasma exchange: Used in severe cases to remove antibodies from the blood.
Prognosis[edit]
The prognosis of anti-AQP4 disease varies depending on the severity and frequency of attacks. Early diagnosis and treatment are crucial to prevent permanent neurological damage.
